Johnson & Johnson (NYSE:JNJ) saw unusually large options trading activity on Thursday. Traders acquired 27,046 call options on the company. This is an increase of 465% compared to the typical daily volume of 4,789 call options.

Shares of Johnson & Johnson (NYSE JNJ) opened at 131.74 on Tuesday. The firm has a market capitalization of $353.59 billion, a P/E ratio of 22.29 and a beta of 0.78. The firm has a 50-day moving average of $132.91 and a 200 day moving average of $127.75. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The business had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.74 earnings per share. On average, equities research analysts expect that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.55%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.

In related news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Harding Loevner LP bought a new stake in shares of Johnson & Johnson during the second quarter worth about $106,000. Lenox Wealth Advisors Inc. raised its stake in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after buying an additional 6 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. Thomas J. Herzfeld Advisors Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter worth about $117,000. Finally, IHT Wealth Management LLC raised its stake in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares during the period. Institutional investors and hedge funds own 65.98% of the company’s stock.

A number of equities analysts have recently commented on the stock. UBS AG reaffirmed a “buy” rating and set a $136.00 target price on shares of Johnson & Johnson in a research report on Monday, May 15th. Cowen and Company set a $147.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Thursday, August 24th. J P Morgan Chase & Co raised their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Tuesday, August 15th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $135.00 target price (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $133.91.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson Sees Unusually Large Options Volume (JNJ)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/29/johnson-johnson-sees-unusually-large-options-volume-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.